Medicenna Strengthens IP Portfolio with U.S. Patent Granted for the Use of Interleukin-2 Superkine Fusion Proteins in Oncology
TORONTO and HOUSTON, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immunotherapy company, today announced the issuance of U.S. Patent No.
- TORONTO and HOUSTON, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immunotherapy company, today announced the issuance of U.S. Patent No.
- The patent further strengthens Medicenna's intellectual property around its BiSKIT™ (Bifunctional SuperKine for ImmunoTherapy) platform.
- The patent protects a new method for enhancing fitness, survival and proliferation of cancer killing effector T cells and NK cells.
- The Company’s Superkine patent estate is currently comprised of 56 granted and 61 pending patent applications.